⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 13, 2025

Table S1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis

Guadalupe Nibeyro Verónica M. Baronetto Agustín Nava María Romina Girotti Laura Prato Gabriel Morón Elmer A. Fernández

View Full Paper

Ask AI

Bookmark

Share

Key Points

Gene fusions were identified as potential prognostic biomarkers in patients with advanced melanoma, enhancing treatment guidance.
The analysis examined correlations between gene fusions and patient outcomes, revealing significant associations.
Retrospective analysis investigated data from diverse patient cohorts, highlighting trends in immune checkpoint blockade responses.
Findings support further research into gene fusions as therapeutic targets for advanced melanoma treatment strategies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective analysis assesses gene fusions as prognostic biomarkers in advanced melanoma, suggesting implications for therapeutic targets.

Abstract

“Characteristics of patients”

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nibeyro et al. (2025) studied this question.

synapsesocial.com/papers/68a36a4f0a429f797332ef85 https://doi.org/10.1158/2767-9764.29900429

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
2Table_S4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
3Table_S3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
4Table_S5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
5Figure 3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025